Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Lab Anim (NY) ; 39(5): 149-54, 2010 May.
Article in English | MEDLINE | ID: mdl-20410899

ABSTRACT

To assess a drug's toxic or carcinogenic effects on neonatal and adult mice and rats, researchers often carry out oral gavage studies. Whether dosed singly or in various combinations, provided as soluble solutions or as colloidal suspensions, the drug must be delivered in accurate and precise doses. For studies that require newborn mice to receive multiple daily doses, delicately handling neonates to increase their chances of surviving is just as critical as the ability to accurately dose small volumes. To help ensure accurate and precise delivery of drug doses ranging from 5 microl for neonatal mice to 400 microl for adults, the authors adapted an automated pipetting system. By slightly modifying standard gavage needles, the authors delivered, on average, 98-99% of targeted dose volumes to neonatal mice.


Subject(s)
Infusion Pumps , Xenobiotics/administration & dosage , Administration, Oral , Animals , Animals, Newborn , Drug Combinations , Female , Male , Mice , Mice, Inbred C3H , Mice, Knockout , Pregnancy , Solutions , Suspensions , Toxicity Tests/methods
2.
Environ Mol Mutagen ; 48(3-4): 270-82, 2007.
Article in English | MEDLINE | ID: mdl-17358030

ABSTRACT

Azidothymidine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI) that is used for reducing mother-to-child transmission of human immunodeficiency virus I. Combinations of AZT and 3'-thiacytidine (3TC) are even more effective than AZT alone. AZT, however, is a mutagen and carcinogen in rodent models and 3TC can increase the genotoxicity of AZT. Since p53 plays a key role in human and mouse tumorigenesis, p53-haplodeficient mice are currently being evaluated as a model for assessing the carcinogenicity of perinatal exposure to NRTIs. In the present study, male C57BL/6 p53(+/+) and p53(-/-) mice were mated with C3H p53(+/+) females; the pregnant females were treated on gestation day 12 through parturition with 40, 80, and 160 mg/kg of AZT or a combination of 160 mg/kg AZT and 100 mg/kg 3TC (AZT-3TC); the p53(+/+) and p53(+/-) offspring were treated daily after birth through postnatal day (PND) 28. The frequencies of micronucleated reticulocytes (MN-RETs) and micronucleated normochromatic erythrocytes (MN-NCEs) were determined on PND1, PND10, and PND28; the frequency of Hprt mutant lymphocytes was measured on PND28. The frequencies of MN-RETs and MN-NCEs were increased in treated animals at all time points; there were no differences in the responses of p53(+/+) and p53(+/-) animals treated with identical doses of NRTIs. After correction for clonal expansion, both AZT and AZT-3TC treatments induced small but significant increases in the frequency of Hprt mutant lymphocytes in p53(+/-) mice, but not in p53(+/+) mice. The data indicate that p53 haplodeficiency affects the genotoxicity of NRTIs; thus, p53(+/-) mice may be a sensitive model for evaluating the carcinogenicity of perinatal exposure to NRTIs.


Subject(s)
Anti-HIV Agents/toxicity , Lamivudine/toxicity , Reverse Transcriptase Inhibitors/toxicity , Zidovudine/toxicity , Animals , Animals, Newborn , Drug Interactions , Female , Hypoxanthine Phosphoribosyltransferase/genetics , Lymphocytes/drug effects , Male , Maternal-Fetal Exchange , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Transgenic , Micronuclei, Chromosome-Defective/chemically induced , Mutation , Pregnancy , Tumor Suppressor Protein p53/deficiency , Tumor Suppressor Protein p53/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...